4 completed. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow tipifarnib: new trials by email Literature Review of tipifarnib trials Research Report on tipifarnib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes alemtuzumab, arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Completed | The University of New South Wales | 2000 | 2006-08-01 | 2013-08-26 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Clinical Observation, Tipifarnib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 144 | 2004-08-18 | 2026-07-14 |
| Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Tipifarnib;Zarnestra; R115777 - Acute Myeloid Leukemia | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 457 | 2004-01-01 | 2016-09-14 |
| Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Gemcitabine with R115777, Gemcitabine with Placebo - Pancreatic Neoplasms | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 688 | 1999-11-01 | 2011-05-19 |
Leukemia, Myeloid, Acute (3) · Anemia, Refractory, with Excess of Blasts (2) · Leukemia, Erythroblastic, Acute (2) · Leukemia, Megakaryoblastic, Acute (2) · Leukemia, Monocytic, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Congenital Abnormalities (1) · Leukemia (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Myelodysplastic Syndromes (1) · Pancreatic Neoplasms (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · National Cancer Institute (NCI) (1) · The University of New South Wales (1)
Israel (1) · Peru (1) · United Kingdom (1) · United States (1)
Alan K. Burnett, MD, FRCP (1) · Selina Luger (1)
U10CA021115 (1), U10CA180820 (1)